Skip to main content
Caplight Logo









MxT Biotech

MxT Biotech

Private
SeoulHealthcare & Life Scienceshttps://mxtbiotech.com

Last Round

Series A

Apr 1, 2022

Total Funding Raised

$4.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

MxT Biotech is a biotechnology company that develops microfluidic platforms for cell engineering and genome editing applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment

Business Model

B2B

Customer Profile

Hardware Sales, Usage-Based SaaS

AI Layer

Non-AI

Keywords

microfluidicscell engineeringintracellular deliverycell and gene therapyCGTgenome editingnon-viral deliverybiotech toolslab equipmentbioprocessingfluidic deformationtransfection alternativeCRISPR deliveryGMP manufacturinglife science hardware

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MxT Biotech Comparables

Compare MxT Biotech with similar companies based on industry and business-model similarity.

MxT Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CellFE
90%
Avectas
84%
Kytopen
82%

MxT Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 1, 2022
SeedJun 2, 2021

Key People

Founding team and executive leadership

Aram Chung

Co-Founder & CEO

Founding Team

MxT Biotech Investors

Notable investors and investment history

MxT Biotech investors
InvestorRounds
Hyundai Investment PartnersSeries A
DAYLI PartnersSeries A
BNK Venture CapitalSeries A
We VenturesSeries A
AJU IB InvestmentSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 445% MoM, reaching 1.5K.

  • Mar 2, 2026

    Monthly visitors grew 299% MoM, reaching 2.8K.

MxT Biotech Filings

Explore SEC and related filing metadata, where available.

MxT Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MxT Biotech's valuation, stock price, and market status.

Is MxT Biotech a public or private company?

MxT Biotech is a private company.

What is the current stock price of MxT Biotech?

MxT Biotech is a private company, so its shares have no public market price. Caplight tracks MxT Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is MxT Biotech worth (valuation)?

Valuation information for MxT Biotech is not publicly available.

Can I buy MxT Biotech stock?

MxT Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was MxT Biotech's last funding round?

MxT Biotech's most recent funding round was Series A on April 1, 2022.

Who are the main investors in MxT Biotech?

Key investors in MxT Biotech include Hyundai Investment Partners, DAYLI Partners, BNK Venture Capital, We Ventures, AJU IB Investment.

Will MxT Biotech IPO soon?

No public IPO plans have been announced for MxT Biotech.

How can I track MxT Biotech secondary market activity?

Caplight tracks bids, offers, and trades in MxT Biotech's shares on secondary markets.

Firmographic Details

HeadquartersSeoul
Employee Range13
Year Founded2021
Last FundingApr 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?